Drug
Cobimetinib clinical trials
Also written Cotellic, GDC-0973 and XL518.
Keep track of what changes. Save the cobimetinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
92 studies that test it; most in 2017 (14)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 2 |
| 2012 | 3 |
| 2013 | 7 |
| 2014 | 5 |
| 2015 | 8 |
| 2016 | 11 |
| 2017 | 14 |
| 2018 | 10 |
| 2019 | 5 |
| 2020 | 6 |
| 2021 | 8 |
| 2022 | 2 |
| 2023 | 4 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
- Melanoma
- 25
Who runs them
Industry 39 · Other 53
Hoffmann-La Roche (20) · Genentech, Inc. (15) · National Cancer Institute (NCI) (4) · OHSU Knight Cancer Institute (4) · M.D. Anderson Cancer Center (3) · Peter MacCallum Cancer Centre, Australia (2) · Hanmi Pharmaceutical Company Limited (2) · City of Hope Medical Center (2)
Often tested with
Tested in the same studies.
Vemurafenib (35) · Atezolizumab (29) · Bevacizumab (12) · Alectinib (10) · Pertuzumab (9) · Abemaciclib (8) · Olaparib (8) · Entrectinib (8)
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Studies
Open first, then newest update. How each study uses cobimetinib is read from its arms, and is right about nine times in ten.
Testing it · 92
- Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic DisordersRecruitingPhase 2Carl AllenNCT04079179Written as Cobimetinib
- A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)RecruitingPhase 2Genentech, Inc.NCT04302025Written as Cobimetinib
- TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage CancerRecruitingPhase 2American Society of Clinical OncologyNCT02693535Written as Vemurafenib and Cobimetinib (CLOSED TO ENROLLMENT)
- Targeted Pathway Inhibition in Patients With Pancreatic CancerRecruitingEarly Phase 1OHSU Knight Cancer InstituteNCT04005690Written as Cobimetinib
- Using Tumor Models to Determine TreatmentsRecruitingPhase 2University Health Network, TorontoNCT06813079Written as Cobimetinib
- Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant MelanomaRecruitingPhase 2Hanmi Pharmaceutical Company LimitedNCT07449754Written as Cobimetinib
- Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E MutationRecruitingPhase 2City of Hope Medical CenterNCT06440850Written as Cobimetinib
- DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.RecruitingPhase 2/3Cancer Research UKNCT05768178Written as Cobimetinib
- The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer DrugsRecruitingPhase 2Helsinki University Central HospitalNCT05159245Written as Cobimetinib
- The Drug Rediscovery Protocol (DRUP Trial)RecruitingPhase 2The Netherlands Cancer InstituteNCT02925234Written as Vemurafenib and Cobimetinib (combination treatment)
- Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway MutationsActive, not recruitingPhase 2University of UtahNCT04409639Written as Cobimetinib
- A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab StudyActive, not recruitingPhase 3Hoffmann-La RocheNCT03768063Written as Cobimetinib
- Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial CancersActive, not recruitingPhase 1National Cancer Institute (NCI)NCT05691504Written as Cobimetinib
- Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive CraniopharyngiomaActive, not recruitingPhase 2Alliance for Clinical Trials in OncologyNCT03224767Written as Cobimetinib
- A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.Active, not recruitingPhase 1Genentech, Inc.NCT04835805Written as Cobimetinib
- A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian TumorsActive, not recruitingPhase 2Hoffmann-La RocheNCT04931342Written as Cobimetinib
- A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingPhase 2/3Hoffmann-La RocheNCT03178552Written as Cobimetinib
- Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung CancerActive, not recruitingPhase 2National Cancer Institute (NCI)NCT03600701Written as Cobimetinib
- A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)TerminatedPhase 1/2Hoffmann-La RocheNCT03281369Written as Cobimetinib
- Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic CancerCompletedPhase 1OHSU Knight Cancer InstituteNCT05034627Written as Cobimetinib
See all 92 studies that test cobimetinib →
Given in every arm · 13 — cobimetinib is usual care beside what is tested
- Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid CancerActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT03181100Written as Cobimetinib
- Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable MelanomaActive, not recruitingPhase 2Fondazione Melanoma OnlusNCT04722575Written as Cobimetinib 20 MG Oral Tablet
- IN10018 Monotherapy and Combination Therapy for Metastatic MelanomaCompletedPhase 1InxMed (Shanghai) Co., Ltd.NCT04109456Written as Cobimetinib
- A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has SpreadCompletedPhase 2Bristol-Myers SquibbNCT02060188Written as Cobimetinib
- A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced MelanomaCompletedPhase 3Hoffmann-La RocheNCT02908672Written as Cobimetinib
- A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid TumorsCompletedPhase 1/2Bristol-Myers SquibbNCT01928394Written as Cobimetinib
- LY3022855 With BRAF/MEK Inhibition in Patients With MelanomaCompletedPhase 1/2Dana-Farber Cancer InstituteNCT03101254Written as Cobimetinib
- Safety and Tolerability of ABM-1310 in Patients With Advanced Solid TumorsTerminatedPhase 1ABM Therapeutics CorporationNCT04190628Written as Cobimetinib
- A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System MetastasesCompletedPhase 2Hoffmann-La RocheNCT03625141Written as Cobimetinib
- A Clinical Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab to Patients With Advanced Platinum-sensitive Ovarian CancerCompletedPhase 1Hoffmann-La RocheNCT03695380Written as Cobimetinib
- A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple MyelomaCompletedPhase 1/2Hoffmann-La RocheNCT03312530Written as Cobimetinib
- A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid TumorsCompletedPhase 2Hoffmann-La RocheNCT03264066Written as Cobimetinib
- Study of Cobimetinib in Participants With Solid TumorsCompletedPhase 1Genentech, Inc.NCT00467779Written as cobimetinib
Codes
What other systems call cobimetinib · ClinicalTrials.gg INT006122
- MeSH (NLM) C574276cobimetinibOne source NLM
- UNII (FDA) ER29L26N1XCOBIMETINIBConfirmed FDA, NLM, Wikidata
- RxNorm 1722365Confirmed FDA, Wikidata
- Wikidata Q15708292cobimetinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C68923CobimetinibOne source FDA
- DrugBank DB05239One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C574276 | cobimetinib | One source NLM |
| UNII (FDA) | ER29L26N1X | COBIMETINIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1722365 | — | Confirmed FDA, Wikidata |
| Wikidata | Q15708292 | cobimetinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C68923 | Cobimetinib | One source FDA |
| DrugBank | DB05239 | — | One source Wikidata |
Also registered as cobimetinib fumarate (UNII 6EXI96H8SV · RxNorm 1722380).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.